Investigation of nepetolide as a novel lead compound: Antioxidant, antimicrobial, cytotoxic, anticancer, anti-inflammatory, analgesic activities and molecular docking evaluation.
Journal: 2018/November - Saudi Pharmaceutical Journal
ISSN: 1319-0164
Abstract:
In the present study, we describe various pharmacological effects and computational analysis of nepetolide, a tricyclic clerodane-type diterpene, isolated from Nepeta suavis. Nepetolide concentration-dependently (1.0-1000 µg/mL) exhibited 1,1-diphenyl,2-picrylhydrazyl free radical scavenging activity with maximum effect of 87.01 ± 1.85%, indicating its antioxidant potential, as shown by standard drug, ascorbic acid. It was moderately active against bacterial strain of Staphylococcus aureus. In brine shrimp's lethality model, nepetolide potently showed cytotoxic effect, with LC50 value of 8.7 µg/mL. When evaluated for antitumor activity in potato disc tumor assay, nepetolide exerted tumor inhibitory effect of 56.5 ± 1.5% at maximum tested concentration of 1000 µg/mL. Nepetolide at 20 mg/kg reduced carrageenan-induced inflammation (P < .001 vs. saline group) in rat paw. Nepetolide dose-dependently (100-500 mg/kg) decreased acetic acid evoked writhes, as exhibited by diclofenac sodium. In-silico investigation of nepetolide was carried out against cyclooxygenase-2, epidermal growth factor receptor and lipoxygenase-2 targets. Virtual screening through Patchdock online docking server identified primarily hydrophobic interactions between ligand nepetolide and receptors proteins. Enhanced hydrogen bonding was predicted with Autodock showing 6-8 hydrogen bonds per target. These results indicate that nepetolide exhibits antioxidant, antibacterial, cytotoxic, anticancer, anti-inflammatory and analgesic activities and should be considered as a lead compound for developing drugs for the remedy of oxidative stress-induced disorders, microbial infections, cancers, inflammations and pain.
Relations:
Content
Drugs
(27)
Similar articles
Articles by the same authors
Discussion board
Saudi Pharm J 26(3): 422-429

Investigation of nepetolide as a novel lead compound: Antioxidant, antimicrobial, cytotoxic, anticancer, anti-inflammatory, analgesic activities and molecular docking evaluation

Department of Pharmacology, Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan
Department of Biological Sciences and Chemistry, University of Nizwa, Nizwa 616, Oman
Department of Chemistry, University of Science and Technology, Bannu, Khyber Pakhtunkhwa, Pakistan
STEM Biotechnology Division, Roxbury Community College, Roxbury, MA, USA
College of Professional Studies, Northeastern University, 350 Huntington Avenue, Boston, USA
Shamsher Ali: ude.uen.yksuh@mahs.ila
Corresponding author. ude.uen.yksuh@mahs.ila
Shamsher Ali: ude.uen.yksuh@mahs.ila
Received 2017 Nov 3; Accepted 2017 Dec 27.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Values shown are mean ± SEM, n = 3.

Values shown are mean ± SEM, n = 3.

Vincristine (250 µg/mL) = 91.3% tumor inhibition. Values shown are mean ± SEM, n = 3.

The results represent the values for the best solution from docking programs. The numbers in parenthesis represent Autodock results.

Footnotes

Peer review under responsibility of King Saud University.

Footnotes
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.